HRP20020334B1 - Proces za pripremu amorfnog kalcij-atorvastatina - Google Patents

Proces za pripremu amorfnog kalcij-atorvastatina

Info

Publication number
HRP20020334B1
HRP20020334B1 HR20020334A HRP20020334A HRP20020334B1 HR P20020334 B1 HRP20020334 B1 HR P20020334B1 HR 20020334 A HR20020334 A HR 20020334A HR P20020334 A HRP20020334 A HR P20020334A HR P20020334 B1 HRP20020334 B1 HR P20020334B1
Authority
HR
Croatia
Prior art keywords
atorvastatin
preparation
calcium
amorphic
heating
Prior art date
Application number
HR20020334A
Other languages
English (en)
Croatian (hr)
Inventor
Greff Zoltn
K�tay Nagy P�ter
Bark�czy J�zsef
Simig Gyula
Bal�zs L�szl�
Dom�n Imre
R�tkai Zolt�n
Seres P�ter
Szent Kir�llyi Zsuzsa
Bartha Ferenc
Vereczkeyn� Don�th Gy�rgyi
Nagy K�lm�n
Original Assignee
Egis Gy�gyszergy�r RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gy�gyszergy�r RT filed Critical Egis Gy�gyszergy�r RT
Publication of HRP20020334A2 publication Critical patent/HRP20020334A2/hr
Publication of HRP20020334B1 publication Critical patent/HRP20020334B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20020334A 1999-10-18 2000-10-17 Proces za pripremu amorfnog kalcij-atorvastatina HRP20020334B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9903634A HU226640B1 (en) 1999-10-18 1999-10-18 Process for producing amorphous atorvastatin calcium salt
PCT/HU2000/000106 WO2001028999A1 (en) 1999-10-18 2000-10-17 Process for the preparation of amorphous atorvastatin calcium

Publications (2)

Publication Number Publication Date
HRP20020334A2 HRP20020334A2 (en) 2004-02-29
HRP20020334B1 true HRP20020334B1 (hr) 2007-12-31

Family

ID=90014241

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020334A HRP20020334B1 (hr) 1999-10-18 2000-10-17 Proces za pripremu amorfnog kalcij-atorvastatina

Country Status (17)

Country Link
EP (1) EP1235800B1 (enExample)
JP (1) JP2003512354A (enExample)
KR (1) KR100664353B1 (enExample)
CN (1) CN1157374C (enExample)
AT (1) ATE345327T1 (enExample)
AU (1) AU1166301A (enExample)
CA (1) CA2388018C (enExample)
CZ (1) CZ300071B6 (enExample)
DE (1) DE60031882T2 (enExample)
HR (1) HRP20020334B1 (enExample)
HU (1) HU226640B1 (enExample)
PL (1) PL354604A1 (enExample)
RS (1) RS50473B (enExample)
RU (1) RU2255932C2 (enExample)
SK (1) SK286861B6 (enExample)
UA (1) UA72777C2 (enExample)
WO (1) WO2001028999A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
DE10135493A1 (de) * 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
JP2005500351A (ja) 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
EP1485343B1 (en) * 2002-03-18 2009-12-23 Biocon Limited Amorphous hmg-coa reductase inhibitors of desired particle size
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
CN1692906A (zh) * 2004-04-30 2005-11-09 鲁南制药集团股份有限公司 治疗高血脂症的组合物
EP3581564A1 (en) 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
KR20090033405A (ko) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ES2072468T3 (es) * 1990-05-11 1995-07-16 American Cyanamid Co Nuevos arilpirroles n-acilados utiles como agentes insecticidas, acaricidas, nematicidas y molusquicidas.
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
SK284973B6 (sk) * 1996-09-20 2006-03-02 Meiji Seika Kaisha Ltd. Kryštalická forma Cefditoren pivoxylu a spôsob jej výroby

Also Published As

Publication number Publication date
HK1050199A1 (en) 2003-06-13
KR20020063166A (ko) 2002-08-01
DE60031882D1 (de) 2006-12-28
HRP20020334A2 (en) 2004-02-29
WO2001028999A1 (en) 2001-04-26
HUP9903634A2 (hu) 2001-12-28
CN1157374C (zh) 2004-07-14
PL354604A1 (en) 2004-01-26
EP1235800A1 (en) 2002-09-04
HUP9903634D0 (en) 1999-12-28
SK286861B6 (sk) 2009-06-05
RS50473B (sr) 2010-03-02
CA2388018A1 (en) 2001-04-26
CA2388018C (en) 2008-04-08
JP2003512354A (ja) 2003-04-02
AU1166301A (en) 2001-04-30
ATE345327T1 (de) 2006-12-15
SK5192002A3 (en) 2002-11-06
KR100664353B1 (ko) 2007-01-02
HU226640B1 (en) 2009-05-28
UA72777C2 (en) 2005-04-15
CN1379760A (zh) 2002-11-13
RU2255932C2 (ru) 2005-07-10
YU28302A (sh) 2005-06-10
HUP9903634A3 (en) 2002-01-28
CZ20021256A3 (cs) 2002-08-14
DE60031882T2 (de) 2007-07-05
EP1235800B1 (en) 2006-11-15
CZ300071B6 (cs) 2009-01-21

Similar Documents

Publication Publication Date Title
DE60031882D1 (de) Verfahren zur herstellung von amorphem atorvastatin kalzium
JP2003512354A5 (enExample)
Wojtas et al. Total synthesis of nosiheptide
BR9907936A (pt) Composição farmacêutica, composto, e, processo para preparar o mesmo
DE69203877D1 (de) Verfahren zur Vernichtung von photokatalytisch abbaubarem, organischem Stoff.
ATE429920T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von hypogonadismus
ATE243672T1 (de) Neue thyroid-rezeptorliganden und verfahren
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
NO961693D0 (no) Delta16-umettede C17-heterocykliske steroider som er anvendbare som steroid C17-20-lyaseinhibitorer
DE69203878D1 (de) Verfahren zur Vernichtung von photokatalytisch abbaubarem, organischem Stoff.
de Figueiredo et al. Sequential One‐Pot Synthesis of Dipeptides through the Transient Formation of CDI‐N‐Protected α‐Aminoesters
DE69303935D1 (de) Verfahren zur Herstellung von 4-Bromomethylbiphenyl-Verbindungen
EA200201017A1 (ru) Кристаллическая форма ii каберголина
TR199900561T2 (xx) G-protein i�levinin engellenmesi i�in ve �o�almaya y�nelik hastal�klar�n iyile�tirilmesi i�in yararl� trisiklik bile�ikler.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
DK0530639T3 (da) Heterocyclisk substituerede quinolylmethoxy-phenylacetamider som lipoxygenasehæmmere
Ingenito et al. Effect of copper salts on peptide bond formation using peptide thioesters
DE60232006D1 (de) Rückgewinnung und recycling chiraler weinsäureverbindungen zur racematspaltung
Lin et al. Stereocontrolled formation of ketomethylene isosteres through tandem chain extension reactions
Kothakonda et al. Synthesis of a novel tetrahydroisoquinolino [2, 1-c][1, 4] benzodiazepine ring system with DNA recognition potential
DE60032453D1 (de) Ein verfahren zur synthese von ritonavir
Airaksinen et al. One-Pot Synthesis of 3, 4-Disubstituted 1 H-Pyrroles from 2-Tropanones
Shirshova et al. Fractions of soil organic substances isolated by resin-alkali extraction technique: study the influence of ecological conditions.
Lo et al. A CD Exciton Chirality Method for Determination of the Absolute Configuration of threo-β-Aryl-β-hydroxy-α-amino Acid Derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081006

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20091018